In addition, c-Kit and FLT3 activate SFKs [20]–[24], and hyperactivation of SFKs occurs in c-Cbl(C379A) mice [25], further supporting the hypothesis that dasatinib may provide an effective treatment for leukemias associated with c-Cbl mutations. Here, CBL is linked to leukemia.